Aakash Desai· @ADesaiMD · X·· 12 hours agoScore70
Body
HERON-Lung01 #ESMO26: HER3 ADC ruzaltatug rezetecan vs platinum-pem, EGFRm NSCLC post-TKI
➡️ mPFS 8.3 vs 5.4 mo, HR 0.47
➡️ ORR 60.0 vs 34.3%
➡️ OS HR 0.70, immature
➡️ ILD 2.4%
Two HER3-targeting ADCs, one session. How do we sequence them?
@LungCancerRx @OncoAlert @oncodaily
35 views · 1 like · 0 reposts · 0 replies
Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgSource: Aakash Desai · x.com